Herceptin (trastuzamab) in advanced breast cancer.
Cancer Treat Rev
; 26(4): 287-90, 2000 Aug.
Article
en En
| MEDLINE
| ID: mdl-10913383
ABSTRACT
Herceptin (trastuzamab, Genentech, San Francisco, CA, USA) prolongs survival in metastatic breast cancer patients whose tumours overexpress the HER2/neu protein. Compared with chemotherapy alone, patients receiving chemotherapy and Herceptin have a significantly longer time to progression, a higher response rate and a longer duration of response. These effects are most marked in first-line treatment of metastatic disease. The addition of Herceptin is associated with few additional side-effects, apart from cardiac toxicity in patients concurrently receiving anthracyclines. As such, it seems reasonable for Herceptin to become considered as one of the routine treatment options in metastatic breast cancer. It would therefore be appropriate for HER2 status testing to be incorporated into the assessment of all patients with metastatic disease. The use of this medication will be limited by its cost. Furthermore, data are lacking on appropriate treatments durations in responders.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Inmunoterapia
/
Anticuerpos Monoclonales
/
Antineoplásicos
Idioma:
En
Revista:
Cancer Treat Rev
Año:
2000
Tipo del documento:
Article